Shots:

• Accent to receive $55M upfront and $1.1B as co-development option and milestone payment- plus royalties and profit split based on the option to co-develop and co-commercialize RMP-targeting therapies for the treatment of cancer in the US
•  Accent will be responsible for research and development activities for a nominated preclinical program through to the end of P-I clinical trials. Post-P-I completion- AstraZeneca will lead development and commercialization activities for the nominated program- with Accent having the option to jointly develop and commercialize with AstraZeneca in the US
• The collaboration combines Accent’s expertise as a leader in the biology- target identification and drug discovery of RMP-targeting therapies with AstraZeneca’s expertise in oncology. Additionally- AstraZeneca is having an option to license two additional preclinical discovery programs- for which Accent will conduct preclinical activities

Click here ­to­ read full press release/ article 

Ref: AstraZeneca | Image:  AstraZeneca